Five COVID-19 Vaccines in China in Stage II Clinical Trials, “Emergency” Solution Ready by End of 2020: Zhong Nanshan


One of China’s top medical experts has told state-owned media that he expects any “emergency” situations in relation to the Novel Coronavirus to be resolvable by the end of 2020.

Zhong Nanshan (钟南山), director of the Guangzhou Institute of Respiratory Diseases and a lead government advisor during the COVID-19 outbreak, said to China Central Television (CCTV) on 29 May that Chinese scientists were at the forefront of global efforts to create a Novel Coronavirus vaccine.

Whether it’s an RNA vaccine or a full virus inactivated vaccine, at present we have five vaccines which have already reached the second stage of clinical tests. Our speed isn’t at all slow.

Of course, research and development of a vaccine requires a considerably long-period of time, but I feel that based on current progress certain emergency [conditions] should be completely solvable by the end of the year.

State-owned Sinopharm announced at the end of May that its initial tests of a Novel Coronavirus inactivated vaccine had proved successful, with the initial group of test subjects including Sinopharm chair Liu Jingzhen (刘敬桢).

Sinopharm has completed construction of a new plant in Beijing for the production of a Novel Coronavirus vaccine, which will have an annual dosage capacity of 100 million.

The company also expects to complete construction on a vaccine plant in Wuhan which will have a similar dosage production capacity.

Related stories

Sinopharm Chair­man Says COVID-19 Vac­cine Has Proven Suc­cess­ful af­ter Serv­ing as Test Sub­ject Him­self

Coro­n­avirus Vac­cine Trial in Wuhan Has Proven Suc­cess­ful Ac­cord­ing to Peer-Re­viewed Lancet Re­port

China Builds World’s Biggest Vac­cine Plant,100 Mil­lion Dose Ca­pac­ity to Be Used for COVID-19 Vac­cine